TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25424601
Drug: Vitamin D3-fortified
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3-fortified doogh (FD; containing 500 IU/250 ml)
Study: 25424601
Drug: Plain doogh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain doogh (PD; containing 150 mg calcium and no vitamin D/250 ml)
Study: 21140164
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) 1 mg/day for 7 days
Study: 16137053
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (TV = 7 ml/kg, f=12 bpm)
Study: 16137053
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (TV=5 ml/kg, f=15 bpm)
Study: 16137053
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (TV=7 ml/kg, f=15 bpm)
Study: 10895409
Drug: Adenosine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (20 mg/10 min)
Study: 8222787
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 50, 100, 200, and 400 micrograms twice daily
Study: 3513105
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (Salbutamol)
Study: 31752498
Drug: Dosing practices
Normalized name: Practical Alchemy Purify and Protect Duo KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing practices based on current recommendations (46%-76% adherence)
Study: 31752498
Drug: Lean body
Normalized name: Cleanser Topical application Soap [NIVEA MEN ACTIVE CLEAN BODY WASH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean body weight for dosing propofol, non-depolarising muscle relaxants, sugammadex, and opioids
Study: 31752498
Drug: Total body
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total body weight for dosing suxamethonium
Study: 31752498
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of resources to assist dosing practices in obesity
Study: 31752498
Drug: Increased incidences
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased incidences of adverse events related to drug dosing
Study: 29659887
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in HOMA-IR on study treatment
Study: 27598803
Drug: High-dose external
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose external beam radiation therapy (EBRT) up to 80 Gy plus androgen deprivation therapy (ADT) for 2 to 3 years
Study: 15798459
Drug: Complete clamping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete clamping (CC)
Study: 14564429
Drug: Desmopressin nasal
Normalized name: desmopressin nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin nasal spray (test preparation)
Study: 6641534
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (20 micrograms HBs antigen, 3 doses at 0, 1, 6 months)
Study: 6641534
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (40 micrograms HBs antigen, 3 doses at 0, 1, 6 months)
Study: 6641534
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (40 micrograms HBs antigen, 5 doses at 0, 1, 2, 4, 6 months)
Study: 6641534
Drug: Passive-active vaccination
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive-active vaccination (40 micrograms HBs antigen at 0, 1, 2, 4, 6 months + 3 ml hepatitis B immunoglobulin at 0, 2 months)
Study: 6641534
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (3 doses at 0, 1, 6 months)
Study: 26465403
Drug: Injection with
Normalized name: Temsirolimus 25mg/1mL Solution for injection with Diluent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection with saline
Study: 26465403
Drug: Injection with
Normalized name: Temsirolimus 25mg/1mL Solution for injection with Diluent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection with anesthetic
Study: 23102084
Drug: Single-dose cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose cefazolin (1 g) during surgery
Study: 23102084
Drug: Multiple-dose antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose antimicrobial prophylaxis (5 doses every 12 hours postoperatively)
Study: 19445860
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone (375 microg, once daily for 3 months)
Study: 11354303
Drug: Prosorba column
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prosorba column treatment
Study: 9753292
Drug: CL 316,243
Approvals — FDA: no, EMA: no, PMDA: no
Description: CL 316,243 (1,500 mg/day)
Study: 31344188
Drug: Watsu therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watsu therapy
Study: 25590673
Drug: Chlorella vulgaris
Normalized name: CHLORELLA VULGARIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorella vulgaris supplement for 2 weeks
Study: 22001994
Drug: Pramipexole (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (0.7 mg free base, 3 times a day)
Study: 22001994
Drug: Ropinirole (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (12 mg, once daily)
Study: 22001994
Drug: Levodopa/Carbidopa (100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/Carbidopa (100/25 mg, 3 times a day)
Study: 17023095
Drug: 9-valent conjugate
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent conjugate pneumococcal vaccine
Study: 8844631
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral conjugated equine estrogen 0.625 mg daily
Study: 8844631
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal estradiol-17 beta 50 mcg twice weekly
Study: 23451547
Drug: Single take
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single take home dose of infant nevirapine
Study: 16368848
Drug: Monitoring group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring group: tracheal intubation at maximum block based on monitoring after atracurium 0.5 mg/kg
Study: 16368848
Drug: 2‐min group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐min group: tracheal intubation 2 min after injection of atracurium 0.5 mg/kg
Study: 10376236
Drug: Clonazepam (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (1-4 mg/d, flexible dose)
Study: 1794360
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg/day
Study: 29744754
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser treatment for seven sessions at 2-week intervals
Study: 29744754
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser treatment for three sessions at 6-week intervals
Study: 25321188
Drug: buprenorphine/naloxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: buprenorphine/naloxone treatment for 4 weeks followed by dose tapering over 7 days
Study: 25321188
Drug: buprenorphine/naloxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: buprenorphine/naloxone treatment for 4 weeks followed by dose tapering over 28 days
Study: 20520636
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of abnormal FLC estimate and/or presence of high-risk IgH translocation
Study: 11600561
Drug: Cromone treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromone treatment (control group)
Study: 7991907
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural block with bupivacaine (8 ml of 0.5% bupivacaine with adrenalin 1:200.000) administered 30 min before surgery and combined anesthesia with isoflurane.
Study: 7991907
Drug: Conventional balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional balanced anesthesia with isoflurane and endovenous fentanyl (2.5 micrograms/kg) and saline solution administered through an epidural catheter.
Study: 2575367
Drug: Cicletanine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine (50 to 100 mg/day) combined with beta-blockers
Study: 2575367
Drug: Cicletanine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine (50 to 100 mg/day) combined with calcium inhibitors
Study: 2575367
Drug: Cicletanine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine (50 to 100 mg/day) combined with angiotensin-converting enzyme inhibitors
Study: 2575367
Drug: Cicletanine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine (50 to 100 mg/day)
Study: 182348
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments combined (Stage III and IV patients)
Study: 30550135
Drug: Intratympanic injection
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic injection of dexamethasone 0.5 ml
Study: 30550135
Drug: Postauricular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postauricular injection of methylprednisolone 40 mg
Study: 26499352
Drug: Probiotics group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics group A (1 g Clostridium butyricum MIYAIRI twice daily)
Study: 26499352
Drug: Probiotics group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics group B (Bifidobacterium longum BB536 twice daily)
Study: 26499352
Drug: Digestive enzymes
Normalized name: DIGESTIVE ENZYMES TAB,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digestive enzymes group (Aczym, containing 100 mg takadiastase N, 20 mg cellulase AP, 50 mg lipase MY, and 100 mg pancreatin, twice daily)
Study: 21878847
Drug: Topical dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dorzolamide 2%-timolol 0.5% twice a day
Study: 17343821
Drug: Pre-treatment SSRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment SSRI use
Study: 17343821
Drug: Post-treatment SSRI
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment SSRI use
Study: 17343821
Drug: Pre-treatment A/D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment A/D use
Study: 17343821
Drug: Post-treatment A/D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment A/D use
Study: 17343821
Drug: Pre-treatment BZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment BZ use
Study: 9334143
Drug: Pefloxacin mesylate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin mesylate, administered twice a day in a daily dose of 0.8 to 1.2 g
Study: 3440039
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available reference preparation
Study: 31524967
Drug: Microneedling followed
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling followed by topical application of 5-fluorouracil
Study: 26786148
Drug: P1000/Ca0 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: P1000/Ca0 (1 g/d phosphorus)
Study: 26786148
Drug: P1000/Ca500 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: P1000/Ca500 (1 g/d phosphorus and 0.5 g/d calcium)
Study: 26786148
Drug: P1000/Ca1000 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: P1000/Ca1000 (1 g/d phosphorus and 1 g/d calcium)
Study: 17373141
Drug: Antiviral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral and analgesic therapies
Study: 17373141
Drug: Childhood vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Childhood vaccine against varicella zoster virus
Study: 17373141
Drug: More potent
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More potent vaccine against varicella for adults
Study: 14649578
Drug: Fibrin sealant
Normalized name: FIBRIN SEALANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin sealant (FS) 10 mL total
Study: 11001889
Drug: Prophylactic methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic methylprednisolone (0.5 mg/kg on days 14 to 20, 1 mg/kg on days 21 to 34, 0.5 mg/kg on days 35 to 48, tapered and discontinued on day 110)
Study: 3307283
Drug: Analgetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgetic treatment without immobilization
Study: 26156412
Drug: CoQ10 supplementation
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 supplementation (100 mg once a day for 12 weeks)
Study: 21779958
Drug: Idebenone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone at a weight-adjusted dose of 1,350/2,250 mg/day for 12 months
Study: 21779958
Drug: Idebenone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone at a weight-adjusted dose of 450/900 or 1,350/2,250 mg/day for 6 months (during the IONIA study)
Study: 21779958
Drug: Idebenone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone at a weight-adjusted dose of 1,350/2,250 mg/day for 12 months (IONIA-E study)
Study: 19176289
Drug: Interferon‐beta (IFNbeta)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐beta (IFNbeta) treatment
Study: 12475391
Drug: BATT 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BATT 10 mg
Study: 12475391
Drug: BATT 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BATT 20 mg
Study: 12475391
Drug: BATT 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: BATT 30 mg
Study: 3341564
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of EMLA cream for 15 minutes
Study: 3341564
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of lidocaine
Study: 3341564
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of EMLA cream for 80 minutes
Study: 3341564
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of EMLA cream for 100 minutes
Study: 3341564
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of EMLA cream for 120 minutes
Study: 30212404
Drug: 100% daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% daily dosing of TDF/FTC for 12 weeks
Study: 30212404
Drug: 67% daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 67% daily dosing of TDF/FTC for 12 weeks
Study: 30212404
Drug: 33% daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33% daily dosing of TDF/FTC for 12 weeks
Study: 28399933
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of ketamine (4.0 mg/kg, maximum 100 mg) and midazolam (0.2 mg/kg, maximum 5.0 mg)
Study: 28399933
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of ketamine (4.0 mg/kg, maximum 100 mg) and midazolam (0.5 mg/kg, maximum 20 mg)
Study: 28399933
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of midazolam (1.0 mg/kg, maximum 20 mg)
Study: 23982225
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) focusing on behavioral exposure
Study: 10934672
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg + Irbesartan 300 mg
Study: 1477436
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine 140 micrograms/kg/min for six minutes
Study: 1477436
Drug: Oral dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dipyridamole suspension 300 mg
Study: 1477436
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine and oral dipyridamole
Study: 27955682
Drug: Telehealthcare (Telekit)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealthcare (Telekit) solution
Study: 15611784
Drug: Capsaicin capsules
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin capsules (0.9 g red pepper; 0.25% capsaicin; 80,000 Scoville Thermal Units)
Study: 15611784
Drug: Capsaicin in
Normalized name: capsaicin in castor oil 0.035 % TOPICAL LIQUID (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin in tomato juice (0.9 g red pepper; 0.25% capsaicin; 80,000 Scoville Thermal Units)
Study: 15611784
Drug: Placebo (offered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (offered in tomato juice or capsules)
Study: 15611784
Drug: Capsaicin conditions
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin conditions (both oral and gastrointestinal)
Study: 10417874
Drug: Ajoene (0.6%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ajoene (0.6%, gel)
Study: 10417874
Drug: Terbinafine (1%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (1%, cream)
Study: 8524604
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation of the tibialis anterior muscle for 4 weeks at twice the motor threshold
Study: 8524604
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation for 4 weeks at twice motor threshold
Study: 2196942
Drug: Elastosis and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elastosis and presence of estrogen and progesterone receptors
Study: 25948515
Drug: Focused extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Focused extracorporeal shock wave therapy (0.25 mJ/mm(2)) with three sessions of 2000 impulses in weekly intervals
Study: 25948515
Drug: Focused extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Focused extracorporeal shock wave therapy (0.25 mJ/mm(2))
Study: 23624419
Drug: Vildagliptin 50mg
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin 50mg twice a day in addition to metformin
Study: 23624419
Drug: Vildagliptin+metformin
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin+metformin
Study: 23624419
Drug: Placebo+metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo+metformin
Study: 21784309
Drug: Calcium tablet
Normalized name: Vinate Calcium Tablet
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium tablet (600 mg once daily as CaCO3)
Study: 21784309
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily
Study: 18795291
Drug: Erlotinib 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 50 mg daily with standard-dose cetuximab
Study: 18795291
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg biweekly
Study: 16915874
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for 12 weeks
Study: 15553594
Drug: n‐3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 PUFA 6.6 g
Study: 15553594
Drug: n‐3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 PUFA 2.0 g
Study: 9062368
Drug: oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral acyclovir 400 mg PO twice a day
Study: 29071464
Drug: Glucagon infusion
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon infusion (elevated blood glucose levels)
Study: 17938811
Drug: Lower tertile
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower tertile platelet count (<198 x 10(9)/L)
Study: 17938811
Drug: Middle tertile
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle tertile platelet count (198-244 x 10(9)/L)
Study: 17938811
Drug: Upper tertile
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper tertile platelet count (>244 x 10(9)/L)
Study: 11911935
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g amino-acid drink without tryptophan (depletion condition)
Study: 11911935
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g amino-acid drink with tryptophan (placebo condition)
Study: 9717598
Drug: Diltiazem (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.2 mg.kg‐1)
Study: 334028
Drug: Oestriol succinate
Normalized name: Oestriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestriol succinate therapy (2 mg/day)
Study: 334028
Drug: Oestriol succinate
Normalized name: Oestriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestriol succinate therapy
Study: 28408545
Drug: Multifaceted service
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted service involving a pharmacist integrated into a medical centre to assist patients after hospitalisation; includes follow-up and medication reconciliation.
Study: 18410408
Drug: Oral acitretin
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acitretin 0.4 mg kg(‐1) daily